Claims
- 1. A compound of formula (I)
- 2. A compound of claim 1 wherein
A is situated in the meta or para position and represents, 30wherein R is hydrogen;
—ORa; —NRaRb, wherein Rb represents hydrogen, alkyl, aryl, alkylaryl, cyano, —OH, —Oalkyl or —Oalkylaryl; R1 is cyano;
—ORd; —O—[CH2]m—ORa; R2 is hydrogen or alkyl; R3 is hydrogen or alkyl; R4 is hydrogen; n is an integer 2-4; D is situated in the ortho, meta or para position and represents 31D′ is situated in the ortho, meta or para position and represents hydrogen, alkyl, alkylaryl, halogen, —CN or —NO2;
—ORh; D″ is situated in the ortho, meta or para position and represents hydrogen, alkyl, alkylaryl, halogen, —CN or —NO2; —ORh.
- 3. A compound of formula I, as claimed in claim 2, wherein
A is situated in the meta or para position; R is —ORa, wherein Ra is hydrogen, alkyl or alkylaryl;
—NHRb, wherein Rb is hydrogen, alkyl, alkylaryl, cyano, —Oalkyl or —Oalkylaryl; R1 is —Oalkyl; R2 is hydrogen or alkyl; R3 is hydrogen or alkyl; R4 is hydrogen; n is an integer 2-4, D is situated in the para position and represents 32wherein Ra and Rf are as defined in claim 3;D′ is hydrogen. D″ is hydrogen.
- 4. A compound of formula I, as claimed in claim 3, wherein
A is situated in the para position; R is —OH, —Oalkyl or —Oalkylaryl;
—NH2, —NHOalkylaryl or —NHCN; R1 is —Oalkyl; R2 is hydrogen; R3 is hydrogen; n is the integer 2 to 3; D is situated in the para position, and represents, 33wherein Ra is as defined in claim 3 and Rf represents hydrogen, alkyl or —OCORd, wherein Rd as defined in claim 1.
- 5. A compound of claim 4, wherein
D represents 34wherein Ra is alkyl or aryl and Rf is as defined in claim 4.
- 6. A compound of claim 5, wherein R is —OH, —Oalkyl or —Oalkylaryl.
- 7. A compound of claim 7, wherein D represents
- 8. A compound according to claim 1 selected from:
3-{4-[(4-{[anilino(methylimino)methyl]amino }phenethyl)oxy]phenyl}-2-ethoxypropanoic acid; 3-{4-[(4-{[anilino(phenylimino)methyl]amino}phenethyl)oxy]phenyl}-2-ethoxypropanoic acid; 3-(4-{[4-({[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl}amino)-phenethyl]oxy}phenyl)-2-ethoxypropanoic acid; 3-(4-{[4-({[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl }amino)-phenethyl]oxy}phenyl)-2(S)-ethoxypropanoic acid; (2S)-3-(4-{4-[4-({[(tert-butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl}-amino)phenyl]butoxy}phenyl)-2-ethoxypropanoic acid; or (2S)-3-(4-{3-[4-({[(tert-Butoxycarbonyl)amino][(tert-butoxycarbonyl)imino]methyl}amino)phenyl]propoxy}phenyl)-2-ethoxypropanoic acid; and pharmaceutically acceptable salts thereof.
- 9. A compound as claimed in any claim from 1 to 8 for use as a medicament.
- 10. A pharmaceutical formulation comprising a compound of any claim from 1 to 8 and a pharmaceutically acceptable adjuvant, diluent or carrier.
- 11. A method for the treatment or prophylaxis of conditions associated with a patient having reduced sensitivity to insulin comprising administering to a patient a compound of any claim from 1 to 8.
Priority Claims (1)
Number |
Date |
Country |
Kind |
0101386-1 |
Apr 2001 |
SE |
|
RELATED APPLICATIONS
[0001] This application is a national stage filing under 35 U.S.C. 371 of International Application PCT/SE02/00770, filed Apr. 18, 2002, which claims priority from Sweden Application No. 0101386-1, filed Apr. 20, 2001, the specifications of each of which are incorporated by reference herein. International Application PCT/SE02/00770 was published under PCT Article 21(2) in English.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/SE02/00770 |
4/18/2002 |
WO |
|